Tekla Capital Management’s Kite Pharma, Inc. KITE Stock Holding History

Tekla Capital Management’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-46,500	Closed	-$2.68M	–	141
2015 Q1	$2.68M	Buy	+46,500	New	+$3.12M	0.11%	100

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Tekla Capital Management's KITE Position: Q3 2016 in Review

Tekla Capital Management sold out of Kite Pharma, Inc. (KITE) in Q3 2016, closing a stake of 41,000 shares — an estimated $2.05M sold.

Tekla Capital Management first reported a position in KITE in Q1 2015 and held it in 6 quarters. The position peaked at $2.68M in Q1 2015. 195 funds tracked by Wall St. Rank hold KITE as of Q3 2016.

Tekla Capital Management reported no remaining Kite Pharma, Inc. position as of Q3 2016 after selling out during the quarter.
Tekla Capital Management sold 41,000 Kite Pharma, Inc. shares in Q3 2016, an estimated $2.05M.
Tekla Capital Management first reported a position in Kite Pharma, Inc. in Q1 2015 and held it in 6 quarters.
Tekla Capital Management's Kite Pharma, Inc. position peaked at $2.68M in Q1 2015.
195 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2016.

Based on Tekla Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.